Free Trial

KBC Group NV Has $351,000 Holdings in Masimo Corporation (NASDAQ:MASI)

Masimo logo with Medical background

KBC Group NV lowered its stake in shares of Masimo Corporation (NASDAQ:MASI - Free Report) by 89.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,105 shares of the medical equipment provider's stock after selling 17,017 shares during the quarter. KBC Group NV's holdings in Masimo were worth $351,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Jones Financial Companies Lllp acquired a new position in shares of Masimo during the fourth quarter valued at $27,000. Farther Finance Advisors LLC lifted its position in Masimo by 128.9% during the 1st quarter. Farther Finance Advisors LLC now owns 206 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 116 shares during the period. EverSource Wealth Advisors LLC boosted its stake in shares of Masimo by 40.0% in the 4th quarter. EverSource Wealth Advisors LLC now owns 224 shares of the medical equipment provider's stock valued at $37,000 after purchasing an additional 64 shares during the last quarter. Smartleaf Asset Management LLC lifted its holdings in Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after buying an additional 60 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in Masimo in the fourth quarter valued at approximately $46,000. Institutional investors and hedge funds own 85.96% of the company's stock.

Masimo Stock Down 3.1%

Shares of MASI traded down $5.12 on Monday, hitting $162.45. The company's stock had a trading volume of 832,123 shares, compared to its average volume of 640,060. The firm's fifty day moving average price is $161.86 and its 200-day moving average price is $166.39. Masimo Corporation has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $8.81 billion, a price-to-earnings ratio of -17.72 and a beta of 1.19.

Masimo (NASDAQ:MASI - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a negative net margin of 25.06% and a positive return on equity of 22.56%. The company had revenue of $372.00 million during the quarter, compared to analysts' expectations of $367.79 million. During the same quarter in the prior year, the company earned $0.77 earnings per share. The business's quarterly revenue was down 24.5% compared to the same quarter last year. On average, equities research analysts expect that Masimo Corporation will post 4.1 EPS for the current year.

Analyst Ratings Changes

Several analysts have commented on the stock. Piper Sandler reiterated an "overweight" rating and set a $200.00 target price (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Wells Fargo & Company decreased their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research report on Thursday, April 10th. Finally, BTIG Research set a $193.00 target price on shares of Masimo and gave the stock a "buy" rating in a report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, Masimo currently has an average rating of "Moderate Buy" and an average target price of $191.60.

Check Out Our Latest Stock Report on MASI

Insiders Place Their Bets

In other Masimo news, COO Bilal Muhsin sold 10,000 shares of Masimo stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the sale, the chief operating officer owned 24,172 shares of the company's stock, valued at $3,946,804.16. This trade represents a 29.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 16.90% of the company's stock.

About Masimo

(Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Featured Stories

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Should You Invest $1,000 in Masimo Right Now?

Before you consider Masimo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.

While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines